Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen says obesity drug caused up to 20% weight loss
Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms
Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss at 52 weeks. Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year,
Why Amgen's Weight Loss Result Is a Win for Eli Lilly
Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight management candidate. According to the giant drugmaker, treatment with an anti-obesity candidate called MariTide helped patients reduce their weight by up to 20% after 52 weeks.
Amgen Drug Delivers More Weight Loss Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
1d
What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
Seeking Alpha
20h
Amgen: Checks All The Wrong Boxes
In the case of
Amgen
(NASDAQ:AMGN), I can honestly say I knew very little about the stock beyond its name and sector for a ...
FierceBiotech
1d
Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
11h
Hold Rating on Amgen’s Maritide Amid Uncertainties in Efficacy and Tolerability
Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Amgen (AMGN – Research Report). The associated price target ...
12h
Amgen's Phase 2 Results Were Not Bad, Don't Let Mr. Market Fool You
Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
MariTide
weight loss
obesity drug
General Motors
Ozempic
Feedback